Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 05:15:25 2024-03-28 am EDT 5-day change 1st Jan Change
543.9 CHF +1.59% Intraday chart for Lonza Group AG +3.71% +53.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Super Micro Computer, Boeing, Vale, Tesla, Nvidia, Intel, Nasdaq... Our Logo
Transcript : Lonza Group AG - Special Call
Singaporean Shares Rise Tracking Global Gains; Top Glove’s Shares Up 9% as Losses Shrink MT
Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche DJ
Luxury stocks drag European equities lower ahead of Fed meeting RE
Lonza Group to Acquire Biologics Site in US for $1.2 billion MT
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion DJ
Lonza to Buy US Biologics Manufacturing Site from Roche for $1.2 Billion MT
Lonza to buy biologics site from Roche in US for $1.2 bln RE
Lonza to acquire biologics site from Roche in U.S. for $1.2 billion RE
Lonza Group AG entered into an agreement to acquire Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG for $1.2 billion. CI
Lonza, Epsilogen Report GMP Manufacturing of Ovarian Cancer Antibody MT
LONZA GROUP : Some mixed real-world effects Alphavalue
Deutsche Bank Lifts Price Target on Lonza Group, Upgrades Recommendation to Buy From Hold MT
AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Add Recommendation MT
Can Novartis dethrone Roche as the largest Swiss Pharma? Alphavalue
AlphaValue/Baader Europe Lifts Price Target on Lonza Group MT
Health Care Up, But Insurers Slip on Week -- Health Care Roundup DJ
LONZA GROUP : Greater optimism into 2024 Alphavalue
Swiss Market Index Soars on Boost from Lonza, Luxury Stocks MT
Global markets live: LVMH, Intel, Tesla, Salesforce, Eli Lilly... Our Logo
Transcript : Lonza Group AG, 2023 Earnings Call, Jan 26, 2024
Correction: Switzerland's Lonza Posts Lower FY23 Profit; Revenue Rises MT
European Midday Briefing : Stocks Rise as Luxury Goods, Spirits Gain DJ
Lonza Shares Rise on Sales, Earnings Beat DJ
Chart Lonza Group AG
More charts
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
535.4 CHF
Average target price
552.4 CHF
Spread / Average Target
+3.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Lonza Group AG - Swiss Exchange
  4. News Lonza Group AG
  5. Lonza : Mirabaud Securities Lifts Price Target on Lonza Group, Maintains Buy Recommendation